Compare Vale SA (VALE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vale SA vs GeneDx Holdings Corp — how do they compare? Vale SA trades at $15.42 (market cap $65.56B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Vale SA is far larger — about 25.6× GeneDx Holdings Corp's market cap, and Vale SA pays a 7.65% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| VALE | WGS | |
|---|---|---|
Market Cap | $65.56B | $2.56B |
Sector | Basic Materials | Technology |
52-Week High | $17.82 | $167.51 |
52-Week Low | $10.50 | $34.51 |
Enterprise Value | $81.80B | $2.60B |
Dividend Yield | 7.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VALE trades at $15.56, up 1.9% on the day, with a bullish technical signal from moving averages and a consensus price target of $16.79. Recent earnings missed estimates for Q4 2025 and Q1-Q2 2026, with net income margin declining to 5.11% in 2025. The company maintains strong operating cash flow of $8.80B and announced a $0.40 dividend for H2 2026. Iron ore demand remains stable per the CFO, while base metals growth offsets cost pressures.
VALE presents a mixed outlook: bullish technicals and analyst support contrast with earnings misses and margin compression. The stock offers value near consensus targets with dividend income, but faces risks from rising costs, volatile commodity prices, and legal liabilities from past dam incidents. Upside depends on execution in copper growth and cost control.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
